Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Dyadic International, Inc. (NASDAQ:DYAI) has announced an interview with CEO Mark Emalfarb on FOX Business Network's The Claman Countdown on December 9, 2020, at 3:15 PM ET. The discussion will highlight the company’s proprietary C1 gene expression platform, aimed at reducing production costs and enhancing the efficacy of biologic vaccines and drugs. Dyadic is focused on advancing its biopharmaceutical technology and expanding its market opportunities to improve healthcare access and affordability.
On November 12, 2020, Dyadic International (NASDAQ:DYAI) reported its financial results for Q3 2020, highlighting a solid cash position of $30.5 million and six new collaborations in animal and human health. Despite a net loss of $2.5 million, compared to $1.7 million a year prior, R&D revenue slightly decreased to $416,000. The company announced significant advancements in its COVID-19 programs, working with multiple research institutions. Collaborative efforts in the Asia Pacific region are expanding, notably with Jiangsu Hengrui Medicine, enhancing Dyadic's market presence.
Dyadic International, Inc. (NASDAQ:DYAI) announced it will release its financial results for Q3 2020 on November 12, 2020, after market close. A conference call will follow on the same day at 5:00 p.m. ET to discuss the results. Dyadic focuses on enhancing its proprietary C1 expression system for biologic vaccines and drugs, aiming to lower production costs and improve performance. The company is exploring various biopharmaceutical collaborations and research initiatives, especially in the context of increasing healthcare demands due to an aging population.
Dyadic International (NASDAQ:DYAI) updates on its COVID-19 initiatives, reporting significant achievements with its C1 gene expression platform. The company successfully expressed a SARS-CoV-2 monoclonal antibody and has reached a record production level of 3 g/l in just five days. Collaborations are ongoing, including ten animal trials by seven groups. Dyadic has also entered a non-exclusive technology agreement with Epygen Biotech of India to produce clinical trial materials. The C1 platform aims to enhance vaccine and drug production efficiency, potentially addressing global demand.
Dyadic International, Inc. (NASDAQ:DYAI) announced a collaboration with Jiangsu Hengrui Medicine Co., Ltd. to utilize its proprietary C1 gene expression platform for the development of selected biologic drugs. CEO Mark Emalfarb emphasized the partnership's potential to enhance biomanufacturing efficiency at reduced costs, catering to global demand for vaccines and drugs. Hengrui's R&D President, Dr. Lianshan Zhang, expressed the aim to leverage Dyadic's technology for more cost-effective biotherapeutics production. The collaboration demonstrates C1's capability in drug development and manufacturing.
Dyadic International, Inc. (NASDAQ:DYAI) has announced its participation in several upcoming investor and industry events in September 2020. Key presentations include the H.C. Wainwright Conference on September 14, BPI East on September 22, and the Sidoti & Company Conference on September 23. Additionally, Dyadic will present at the World Vaccine Congress on September 29 and October 1, focusing on its proprietary C1 gene expression platform. This platform aims to enhance the development and production of biologic vaccines and drugs. For further details, visit Dyadic's website.
Dyadic International (NASDAQ:DYAI) announced significant advancements and collaborations in both human and animal health sectors as of August 13, 2020. This includes collaborations with top pharmaceutical companies and initiation of SARS-CoV-2 vaccine trials. The company reported $11.8 million in cash and equivalents, up from $4.8 million at year-end 2019, with a research revenue increase to $524,000. Despite a net loss of $2.65 million for the quarter, Dyadic remains well-positioned financially, filing an S-3 registration for a $50 million stock offering to enhance capital resources.
Dyadic International (NASDAQ:DYAI) announced significant advancements on August 13, 2020, including a fully funded collaboration with a top five global pharmaceutical company for COVID-19 therapeutics. The company is also conducting animal trials for its SARS-CoV-2 vaccine candidate, with promising results. Dyadic's financial position remains strong, with approximately $11.8 million in cash and a $50 million At The Market offering program filed. The company has also expanded its R&D collaborations, reflecting its growing portfolio and potential in the biotechnology market.